Unraveling Cancer Metabolism by Next-Generation Metabolomics
Reprogramming of cell metabolism, including aerobic glycolysis, also known as the Warburg effect, has been increasingly acknowledged as one of the ten hallmarks of cancer. Therefore, metabolomics is an ideal tool for a systemic analysis of the metabolic phenotype of cancer patients, the discovery of biomarkers, and the development of treatment options. In addition, the gut microbiome is becoming of greater importance in understanding (patho-)physiological processes, the development and progression complex diseases like cancer, and response to cancer immunotherapy.
This presentation will provide an overview of recent advancements in the analysis of the cancer metabolome including studies on hepatic, prostate, breast, and colorectal cancer. Overall, there is emerging evidence for mitochondrial metabolic dysfunction to play a key role in tumorigenesis. In recent years, increased levels of toxic homocysteine in plasma have also been shown to be closely related to cancer. Moreover, bile acids are increasingly understood as signaling molecules impacting cancer risk as some are described to exert cytotoxic effects. Importantly, studying metabolites present in the tumor microenvironment where reprogramming of the metabolism of tumor and non-tumor cells occurs is a growing area of cancer research. Combining metabolomics with functional genomics can contribute to identify and understand causal links and metabolic vulnerabilities in cancer cells.
The MxP® Quant 500 kit is the worldwide first standardized solution for multiplexed, targeted quantification of up to 630 metabolites and lipids from 26 analyte classes by mass spectrometry ensuring highly accurate and reproducible results. This next-generation metabolomics kit also covers a multitude of microbiota-derived metabolites and it is applicable to a wide range of matrices including plasma and feces. Hence, the kit also allows for a comprehensive analysis of the cancer metabolism.
Investigation of the cancer metabolism and the functional nutrition-microbiome-host interplay are key aspects to better understand the causal link to pathophysiological processes, cancer development, as well as patient stratification.
Domain 1 - UMR 3347 / U1021 - Normal and pathological signaling